First published 10/3/2026, 12:49:15 AM · Last updated 10/3/2026, 12:49:15 AM

P3.18.81 A Phase II Study of First-Line Sintilimab Combined With Anlotinib and Platinum-Based Chemotherapy in Unresectable MPM

A journal article describes a Phase II clinical study testing first-line sintilimab plus anlotinib with platinum-based chemotherapy for unresectable MPM. The source notes the publisher (Elsevier BV) but provides no results, locations, or participant details.

Illustrative image: Treatments work for some cancers and not others. Each cancer is unique, with different genes involved and therefore different sensitivity to drugs. As cancer cells grow and change, some cells in the same patient may become resistant to a drug. These cells will remain after treatment, causing relapses. — WassermanLab/Wikimedia Commons, CC BY-SA 4.0

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 3/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The study examines a first-line combination therapy regimen for patients with unresectable MPM.

Sources

P3.18.81 A Phase II Study of First-Line Sintilimab Combined With Anlotinib and Platinum-Based Chemotherapy in Unresectable MPM

Report an issue